Marinus Pharmaceuticals(US:MRNS) GlobeNewswire News Roomยท2024-08-02 14:15Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Marinus Pharmaceuticals, Inc. due to alleged violations of federal securities laws, particularly related to misleading statements about the RAISE trial and its implications for the company's operations and stock performance [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Marinus stock or options between March 17, 2021, and May 7, 2024, to discuss their legal rights [1][2]. - A federal securities class action has been filed against Marinus, with a deadline of August 5, 2024, for investors to seek the role of lead plaintiff [2][9]. Group 2: Allegations Against Marinus - The complaint alleges that Marinus and its executives made false and misleading statements regarding the risks associated with the RAISE trial, including the failure to meet early-stopping criteria [4]. - It is claimed that the company did not disclose that failing to meet these criteria could lead to the cessation of the Phase 3 RAISE II trial, resulting in materially false and misleading statements about its business and prospects [4]. Group 3: Stock Performance Impact - Following the April 15, 2024 announcement that the RAISE trial did not meet early stopping criteria, Marinus stock fell by $6.22 per share, or 82.7%, closing at $1.30 [6]. - The stock experienced further decline, dropping an additional $0.10, or 7.69%, to close at $1.20 on April 16, 2024 [6]. - On May 8, 2024, after announcing cost-cutting measures and the cessation of the Phase 3 RAISE II trial, the stock fell by $0.14, or 8.91%, closing at $1.43 [8].